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Background and Objective. To investigate the relationship between optic nerve sheath diameter, optic nerve diameter, visual
acuity and osteopontin, and neurofilament heavy chain in patients with acute optic neuritis. Patients and Methods.
Sonographic and visual acuity assessment and biomarker measurements were executed in 23 patients with unilateral optic
neuritis and in 19 sex- and age-matched healthy controls. Results. ONSD was thicker on the affected side at symptom onset
(median 6.3mm; interquartile range 6.0–6.5) than after 12 months (5.3mm; 4.9–5.6; p < 0 001) or than in controls (5.2mm;
4.8–5.5; p < 0 001). OND was significantly increased in the affected side (3.4mm; 2.9–3.8) compared to healthy controls
(2.7mm; 2.5–2.9; p < 0 001) and was thicker at baseline than after 12 months (2.8mm; 2.7–3.0; p < 0 01). Visual acuity
improved significantly after 12 months (1.00; 0.90–1.00) compared to onset of symptoms (0.80; 0.40–1.00; p < 0 001). OPN levels
were significantly higher in patients at presentation (median 6.44 ng/ml; 2.05–10.06) compared to healthy controls (3.21 ng/ml,
1.34–4.34; p < 0 03). Concentrations of NfH were significantly higher in patients than in controls. Conclusion. ONSD and OND are
increased in the affected eye. OPN and NfH are elevated in patients, confirming the presence of any underlying inflammation and
axonal injury.
1. Introduction
Optic neuritis can be easily investigated because of its well-
defined onset and accessibility to different diagnosticmethods
[1]. The most common pathophysiological mechanism of
optic neuritis is inflammatory demyelination of the optic
nerve.However, axonal degeneration and inflammation coex-
ist in these patients and are associated with visual function
impairment [2, 3].
Although optic neuritis is a clinical diagnosis, investiga-
tions such as retinal optical coherence tomography (OCT)
or MRI may be proven useful in supporting the diagnosis.
These techniques have provided fascinating insights into
the pathophysiology of optic neuritis in its various forms
[4, 5]. Transorbital sonography is a sensitive, highly accessi-
ble, user-friendly, and reliable technique for detecting optic
nerve diameter (OND) and optic nerve sheath diameter
(ONSD) [6] and is also able to show a significant thickening
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of OND and ONSD in the affected side, which is probably
due to inflammation with subsequently increased perineural
subarachnoid fluid [7].
Transorbital sonography and OCT provide different and
complementary information on the pathophysiology of optic
neuritis. Compared to OCT, nerve ultrasonography has an
inferior resolution but can provide a better depiction of the
nerve and the orbita, because OCT is limited to surface
analysis [7].
In a recent systematic review assessing the role of optic
ultrasonography in the diagnosis of acute optic neuritis, this
technique was able to detect an increase of the optic nerve
and sheath diameters in about 80% of affected patients [8].
This finding is consistent with the development of vasogenic
edema and the presence of the early optic nerve lesion, recog-
nizable by the gadolinium leakage often shown in MRI or the
lesions identified with particular sequences of MRI such as
FLAIR sequences [5, 9].
Conversely, OCT accurately documents changes in the
thickness of retinal layers such as swelling in case of acute
optic neuritis with optic disc swelling; this might be proven
further useful, although only one-third of patients with acute
optic neuritis show papillitis [4, 8].
Osteopontin (OPN), a proinflammatory cytokine expressed
in several tissues and pathological conditions [10, 11], was
shown to be increased in the cerebrospinal fluid of patients
with optic neuritis [12]. In multiple sclerosis (MS), OPN levels
correlate with disease severity and relapse rate [13]. On the
other hand, blood levels of neurofilament heavy chain (NfH),
a biomarker for neurodegeneration, are increased in patients
with acute optic neuritis and inversely correlated with visual
loss [14]. Simultaneous assessment of visual acuity, transorbital
sonography, and biomarkers may provide an opportunity to
further explore inflammation and neurodegeneration in optic
neuritis and was therefore the aim of this study.
2. Methods
Written informed consent was obtained from all persons
before entering the study. The studywas approved by the local
ethics committee (Bolzano, number 19-2014) and performed
in accordance with the Declaration of Helsinki.
2.1. Patients’ Inclusion. All consecutive patients presenting to
the Neurology Outpatient Clinic of Merano Hospital
between December 2014 and November 2015 with a clinical
diagnosis of optic neuritis were enrolled. Inclusion criteria
were those adopted in the Optic Neuritis Treatment Trial
by the Opticus Neuritis Study Group: 18–46 years of age;
acute unilateral optic neuritis with visual symptoms for 8
days or fewer; a relative afferent pupillary defect and a visual
field defect in the affected eye; no previous episodes of optic
neuritis in the affected eye; no previous corticosteroid treat-
ment for optic neuritis or multiple sclerosis; and no systemic
disease other than multiple sclerosis that might be the cause
of the optic neuritis [3].
All patients underwent neurologic and ophthalmologic
examinations, including visual acuity assessment and direct
ophthalmoscopy. Laboratory examinations included vasculitis
screening, anti-neuromyelitis optical antibodies (aquaporin4-
antibodies), and antibodies against myelin oligodendrocyte
glycoprotein. MRI was done to exclude other causes of optic
neuritis or compressive lesions [3]. All patients were followed
up for 12 months.
2.2. Procedure of the Study and B-Ultrasound Sonography.
Transorbital sonography, visual acuity, and biomarkers were
assessed at onset (T0) and after 12 months (T12). At first
presentation, transorbital sonography was evaluated by an
expert neurosonologist (PL), who was accredited by the
Italian Medical Ultrasound Society. We did not evaluate the
sensitivity of sonographic data, but high attention was paid
in order to assure quality control for the sonographic data.
The high reliability of this technique has been reported in
previous studies [15, 16]. In order to reduce the variability
of measurements, the ONSD was measured three times in
each eye and the mean values were calculated.
Transorbital sonography was always performed prior to
the initiation of steroid treatment. Afterwards, all included
patients received a single course of one gram of intravenous
methylprednisolone sodium succinate over five days. The
sonographer was unaware of the condition of case or control
and of the affected side. To ensure blinding, patients and
healthy controls were asked not to reveal their status (or their
affected side) during examinations and were always placed
on the examination table before the sonographer’s arrival.
Transorbital sonography was carried out in B-mode using
a Toshiba Applio XG equipped by a 4-11 Megahertz 5 S1
Linear Probe (Toshiba Medical System, Applio Nasu, Japan).
We adopted the same procedure described elsewhere [6, 7].
2.3. Assessment of OPN and NfH. OPN and NfH levels were
determined for all patients presenting with symptoms
suggestive of acute unilateral optic neuritis and before the
beginning of the infusion of methylprednisolone. After
collection, the clotted venous blood was centrifuged at
3000 rpm for 15min to obtain the serum that was then stored
at −80°C until use. OPN and NfH serum levels were mea-
sured using the human OPN DuoSet ELISA development
kit and the ELISA-pNFH-V1 (R&D Systems, Minneapolis,
MN, USA; EnCor Biotechnology Inc., Gainesville, FL, USA,
resp.) according to the manufacturer’s instructions. The
optical density (OD) of each sample was determined at
450 nm with a Spectra Count (Bio-Rad, Hercules, CA, USA),
subtracting the lowest mean OD of the negative control.
Sensitivity for OPN ELISA was 0.0625 ng/ml and for NfH
ELISA was 0.2 ng/ml. Specificity of OPN ELISA kit was tested
with recombinant human MMP-3 prepared at 50ng/ml that
showed no cross-reactivity or interference. Specificity of
NfH ELISA kit was tested with HPLC-purified bovine NfM
(7.8%), with bovine NfL (6.5%), and with bovine GFAP
(0.06%) [17]. All samples were stored at the Clinic of Merano
Hospital and then sent to the University of Novara. Due to a
shortage of patients’ samples, we decided to test OPN in all
samples and NfH in 19 patients.
2.4. Statistical Evaluation. Continuous variables were
described using median and interquartile range (IQR) for
2 Disease Markers
nonparametrically distributed variables and mean with
standard deviation for parametrically distributed variables.
Comparisons between groups were assessed using the
nonparametric Mann–Whitney U test and Wilcoxon signed-
rank test. Correlations were assessed with the Spearman test;
the level of statistical significance was set at p = 0 05.
All analyses were performed using dedicated statistical
software (IBM Statistical Package for Social Science (SPSS),
version 23.0.0.2, Armonk, New York, USA).
3. Results
3.1. Participants. Of the 28 patients who presented with a
newly diagnosed optic neuritis during the study period, 5
did not meet the study criteria and were excluded from fur-
ther analysis (1 missed during follow-up, 4 had potentially
confounding conditions: 1 pituitary adenoma, 1 meningeal
carcinomatosis, 1 neurosarcoidosis, and 1 tuberculum sellae
meningioma). Hence, we had data from 23 patients, of
whom 11 had prior MS relapses without previous optic neu-
ritis and 12 had isolated optic neuritis. We analyzed data
from 19 age-matched healthy controls. Demographic and
clinical characteristics of the included patients and controls
are reported in Table 1.
3.2. Ultrasound and Visual Acuity. Table 2 reports findings on
ONSD, OND, and visual outcomes of both patients and
controls. We observed a significant thickening of ONSD in
the affected side (median 6.3mm, IQR 6.0–6.5) compared to
healthy controls (median 5.2mm, IQR 4.8–5.5; p < 0 001) and
after 12 months (median 5.3mm, IQR 4.9–5.6; p < 0 001).
The median OND in the affected side (3.4mm, IQR 2.9–3.8)
was significantly increased compared to the controls (median
2.7mm, IQR 2.5–2.9; p < 0 001) and after 12 months of
follow-up (median 2.8mm, IQR 2.7–3.0; p < 0 01). Visual
acuity in the affected eye was significantly worse at presentation
(median 0.80, IQR 0.40–1.00) than after 12 months (median
1.00, IQR 0.90–1.00; p < 0 001).
3.3. Biomarkers. Serum OPN levels were significantly higher
in patients with optic neuritis at presentation (median
6.44 ng/ml, IQR 2.05–10.06) compared to healthy controls
(median 3.21 ng/ml, IQR 1.34–4.34; p < 0 03) (Table 3).
Concentrations of NfH were significantly higher in patients
(median 0.39 ng/ml, IQR 0.21–0.55) than in controls
(median 0.02 ng/ml, IQR 0.02–0.08; p < 0 001) (Table 3).
OPN and NfH concentrations remained elevated after 12
months with no statistically significant difference in OPN
(p = 0 24) or NfH (p = 0 94) between T0 and T12.
3.4. Correlations between OPN, NfH, and ONSD.We found a
statistically significant correlation between the ONSD value
in the affected side and serum levels of OPN at T0 (r = 0 68;
p < 0 05). Conversely, no statistically significant correlation
between ONSD in the affected side and NfH level was
observed (r = −0 43; p = 0 09).
3.5. OPN, NfH and Visual Acuity. Statistically significant dif-
ferences were found in serum levels of OPN at T0 between
patients with residual visual deficit and patients showing
complete recovery (medians 7.7 versus 2.6 ng/ml; p = 0 03).
Table 1: Characteristics of patients and controls.
Optic neuritis
Healthy
controls
p value
Number of patients, n (%) 23 (100) 19 (100)
Sex
Females, n (%) 19 (83) 13 (68) 0.47∗
Males, n (%) 4 (17) 6 (32)
Time from onset days 14 (8–26) —
Follow-up days 360 —
Age, years (mean± SD) 33.0± 8.0 34.3± 9.2 0.63∗∗
Isolated optic neuritis, n (%) 12 (52.2)
MS-optic neuritis, n (%) 11 (47.8)
Datawere expressed in frequency (percentage)ormeans ± standarddeviation.
∗Fisher’s exact test. ∗∗t-test for independent groups.
Table 2: Sonographic features and visual outcomes of patients and
OPN and NfH values assessed at baseline (T0) and after 1 year (T12)
of follow-up.
Parameter T
ON patients
affected eye
(n = 23)
Healthy
controls
(n = 19)
p value
ONSD, mm
T0 6.3 (6.0–6.5) 5.2 (4.8–5.5) <0.001
T12 5.3 (4.9–5.6)
p value <0.001
OND, mm
T0 3.4 (2.9–3.8) 2.7 (2.5–2.9) <0.001
T12 2.8 (2.7–3.0)
p value 0.001
Visual acuity
T0 0.80 (0.40–1.00)
T12 1.00 (0.90–1.00)
p value <0.001
T: time; ON: optic neuritis; ONSD: optic nerve sheath diameter, mm;
OND: optic nerve diameter, mm; mm: millimeter; OPN: osteopontin;
NfH: neurofilament heavy chain; ng/ml: nanogramm/milliliter; n: number
of patients. Data are reported as median (IQR).
Table 3: OPN and NfH values assessed at baseline (T0) and after
1 year (T12) of follow-up.
Parameter T Patients∗
Healthy controls
(n = 19) p value
OPN, ng/ml
T0 6.44 (2.05–10.06) 3.21 (1.34–4.34) <0.03
T12 6.70 (3.85–10.90)
p 0.24
NfH, ng/ml
T0 0.39 (0.21–0.55) 0.02 (0.02–0.08) <0.001
T12 0.3 (0.21–0.48)
p 0.94
OPN: osteopontin; NfH: neurofilament heavy chain; ng/ml: nanogramm/
milliliter; n: number of patients. Data are reported as median (IQR). ∗23
patients underwent OPN measurements at T0 and T12, and 19 patients
underwent NfH measurements at T0 and T12.
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Regarding the serum levels of NfH at T0, we observed no
statistically significant difference between patients with visual
deficit at follow-up compared with patients with a good
visual outcome (medians 0.39 versus 0.28 ng/ml; p = 0 291).
OPN values at T12 were significantly higher in patients
with worsened visual acuity compared to patients with
complete recovery of visual function (medians 10.8 versus
4.6 ng/ml; p = 0 019).
Regarding the serum levels of NfH at T12, we observed no
statistically significant difference between the 7 patients with
worsened visual acuity and patients who had regained normal
visual acuity (medians 0.36 versus 0.25 ng/ml; p = 0 236).
4. Discussion
This is the first longitudinal study assessing circulating
biomarkers of inflammation and axonal injury in parallel
with transorbital sonography and visual acuity in patients
with acute optic neuritis. Our approach is quite novel since
we explored translational aspects that are well established in
other neuroinflammatory conditions such as MS [18] but
definitely less studied in optic neuritis [19].
Our study confirms that transorbital sonography is a
sensitive technique for visualizing optic nerve thickening in
the affected eye [7]. Nerve swelling is indeed the direct
expression of the hallmark of optic neuritis, that is, inflam-
mation. Furthermore, transorbital sonography can provide
quantitative observations of the increase of nerve sheaths
determined by the perineural subarachnoid fluid.
NfH and OPN levels were higher in patients with optic
neuritis than in controls and remained elevated even after
12 months. Moreover, OPN concentration was significantly
higher in patients with residual visual deficit after 12 months,
thus supporting its detrimental effect in neuroinflammatory
conditions [20]. Conversely, we did not find a higher concen-
tration of NfH in patients with residual deficit compared to
patients with a complete recovery after 12 months.
Our findings are in line with a previous study showing
higher OPN levels during MS relapses and a direct correla-
tion between OPN levels and disability [21]. Two further
studies confirmed that OPN levels were higher in MS relapse
compared to remission [13, 22].
Other studies found higher concentrations of NfH in
patients with optic neuritis compared to controls or higher
concentrations in patients with optic neuritis and neuromy-
elitis optica with more serious visual impairment compared
to MS patients with optic neuritis or controls [2, 23]. Our
study failed to show a significant relation between higher
NfH concentrations at symptom onset and residual visual
impairment. Conversely, we found a direct correlation
between OPN and both ONSD and OND. Such parameters
can provide complementary information on the dynamics
of inflammation, and therefore, we suggest that they should
be further studied in optic neuritis.
Notwithstanding the significant improvement in visual
acuity, the persistence of high biomarkers concentrations
over time suggests the persistence of underlying inflamma-
tion and neurodegeneration. The ONTT trial has indeed
shown a spontaneous recovery in many but not all patients
over a few weeks in acute idiopathic optic neuritis, even
though the effect of treatment in subgroups was not
analyzed [3].
The main limitation of this study is the small sample size.
Therefore, our results need to be cautiously interpreted and
replicated on a larger population. The use of transorbital
sonography together with biomarkers would be of particular
interest to monitor subgroups of patients with visual loss
progressing for more than 2 weeks and with the absence of
recovery for more than 3 weeks. Our findings were obtained
by a single operator, but they can be easily replicated thanks
to the low inter-rater variability of this technique [6].
Overall, our results support the usefulness of examining
biomarkers in optic neuritis, since they provide complemen-
tary information on pathophysiology. The increase of OPN
and ONSD seems to be correlated with the intensity of
inflammation and might have a prognostic value, in analogy
to what was suggested in MS [24]. Moreover, a similar study
design could be easily applied to test correlations between
ultrasound findings and other circulating molecules with a
potential role in optic neuritis [25].
In conclusion, this study suggests that OPN levels predict
visual outcome and neuronal loss after optic neuritis,
whereas the role of NfH remains to be fully elucidated.
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